Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Flowserve Corporation heads into its October 28 quarterly results with shorts adding exposure and the Street trimming targets, even as options traders remain unusually bullish on the name.
Short interest has climbed steadily over the past month, and the pace picked up this week. Positions grew almost 9% over the past seven days to 7% of the free float, and are up nearly 12% over the past month. That is the highest sustained level since the late-September spike, when SI briefly touched a 30-day peak before retreating sharply around September 28 and then rebuilding. The rebuild into earnings is the clearest signal this week. Borrow conditions remain easy: availability is running at 477%, meaning there are close to five shares available to lend for every one currently borrowed, and cost to borrow is a low 0.56%. Shorts are not paying a premium to hold this position, and there is no squeeze pressure in the lending market. Options tell the opposite story. The put/call ratio at 0.11 is fractionally below its 20-day average and close to its 52-week low of 0.096, which means call volume continues to dominate the options book heavily. Whoever is selling puts or accumulating calls is not hedging into the print, they are positioned for a move higher.
The Street, despite being broadly constructive, has spent recent months trimming targets. RBC Capital lowered its target to $88 from $94 this week while holding an Outperform. Before that, Stifel and RBC both raised targets after the July print, when FLS posted the 8.7% next-day gain its earnings history shows. The mean analyst target is $88.40 against a current price of $71.47, implying roughly 24% upside on consensus, though TD Cowen moved to Hold in June with a $70 target and sits closest to the market. The bull case centres on margin expansion: adjusted operating margins widened 370 basis points year-on-year to 14.8%, beating estimates, with nuclear and power infrastructure bookings cited as durable growth drivers. The bear case is about the top line. Organic sales guidance was cut to 1% to 3%, well below prior expectations, and the company's track record through 2018 to 2022 of flat-to-declining revenues still weighs on valuation debates. At a P/E of 15.8x and EV/EBITDA of 10.7x, both little changed over the past month, FLS trades at a discount to SMID-cap industrials peers, which the bulls see as a margin-expansion re-rating opportunity and the bears see as fair value given growth risks.
The ORTEX short score has drifted higher through October, moving from 49.2 on October 7 to 51.9 on October 12. That is not an extreme reading but the directional drift higher through the week is consistent with the SI rebuild. Factor positioning is mixed: the dividend score ranks in the 75th percentile, EV/EBIT in the 63rd, but short score rank sits in the 18th percentile and days-to-cover in the 12th, both reflecting a market that is not heavily positioned against the stock despite the recent increase. Peer performance was broadly weak on the week. PH fell 3.2%, ESAB dropped 6.9%, and IMI lost 3.9%, so FLS's 2.5% weekly decline is not dramatically out of step with the industrial peer group. That limits the read-through from the SI rebuild: some of it may simply be sector-level caution ahead of a busy earnings calendar.
On historical earnings reactions, the July 2026 print stands out. The stock moved 8.7% the next day and 12.4% over the following five sessions, the sharpest post-earnings move in the recent record. The two entries in the data for that date suggest the move was clean rather than noise. A repeat of that magnitude would take FLS through $77, closing much of the gap to consensus targets.
With the print on October 28, the key question is whether bookings momentum in nuclear and power can offset the guidance trim and reassure the Street that 1% to 3% organic growth is a floor rather than a ceiling.
See the live data behind this article on ORTEX.
Open FLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
